$ANIP

CAREY STEPHEN P. sold $265K of ANIP

CAREY STEPHEN P. (SVP & CFO) sold 3,312 shares of ANI PHARMACEUTICALS INC (ANIP) at $80.00 ($0.26M total) on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAREY STEPHEN P.
Published Jun 9, 2026, 10:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 10:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANIP
Neutral
high confidence
Mentioned
$ANIP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPNeutralLow
01

Why it matters

Insider sales can influence sentiment, but 10b5-1 pre-arranged plans are generally less informative about near-term fundamentals.

02

Market read

Traders may note the scheduled insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article provides only the sale details; it does not indicate changes in operating outlook, financing needs, or new company-specific catalysts.

Relevance 3/10Novelty 5/10Timing: Filed June 9; sale executed June 5

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for ANI Pharmaceuticals, Inc.

Company-level read

Ticker impact

$ANIPNeutralHigh confidence
Context

SEC Form 4 shows ANIP CFO Stephen P. Carey sold 3,312 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale with explicit 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • ANI Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure (ANIP).

  • Stephen P. Carey

    SVP & CFO who sold 3,312 shares on June 5 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANIPHighAI 8/10

ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study

ANI Pharmaceuticals (ANIP) reported positive results from its Phase 4 SYNCHRONICITY trial for the Fluocinolone Acetonide Intravitreal Implant in treating chronic non-infectious uveitis affecting the posterior segment of the eye. The trial met primary endpoints at six months and maintained improvements through 24 months. The implant is approved in the U.S. for chronic NIU-PS and diabetic macular edema. ANIP's stock closed at $73.89, up 2.65%.

$ANIPMedAI 8/10

ANI reports positive results from uveitis implant trial

ANI Pharmaceuticals (NASDAQ:ANIP) reported positive Phase 4 trial results for its fluocinolone acetonide implant in treating chronic non-infectious uveitis. The trial met primary endpoints, showing sustained improvements in visual acuity and central subfield thickness over 24 months. Adverse events included ocular hypertension and cataract. The implant was previously FDA-approved for diabetic macular edema and uveitis treatment.

$ANIPMedAI 8/10

After one implant, 79.6% of treated eyes had no inflammation return for two years

ANI Pharmaceuticals reported 6-month and 24-month data from its SYNCHRONICITY trial of fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis. The trial met co-primary endpoints with statistical significance, showing improvements in visual acuity and central subfield thickness. At 24 months, 79.6% of treated eyes had no inflammation recurrence. Adverse events were consistent with prior trials.

$ANIPMedAI 8/10

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals (ANIP) will present data from its Phase 4 SYNCHRONICITY trial and post-hoc analyses from the NEW DAY trial at the American Academy of Ophthalmology 2026 Meeting. The trials involve Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis and diabetic macular edema. The company also plans an encore presentation at the Hawaiian Eye & Retina 2027 Meeting.